Ensign Peak Advisors Inc Grows Stock Holdings in Humana Inc. (NYSE:HUM)

Ensign Peak Advisors Inc raised its stake in shares of Humana Inc. (NYSE:HUM) by 51.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 782,302 shares of the insurance provider’s stock after acquiring an additional 264,346 shares during the period. Ensign Peak Advisors Inc owned approximately 0.65% of Humana worth $292,307,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in HUM. CarsonAllaria Wealth Management Ltd. lifted its holdings in shares of Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the period. Hantz Financial Services Inc. acquired a new stake in shares of Humana in the 2nd quarter worth $35,000. Family Firm Inc. purchased a new stake in shares of Humana in the second quarter valued at about $37,000. Hollencrest Capital Management acquired a new position in shares of Humana during the second quarter worth about $40,000. Finally, Riverview Trust Co purchased a new position in Humana during the second quarter worth about $44,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on HUM shares. Baird R W raised Humana to a “hold” rating in a research note on Thursday, May 30th. Oppenheimer increased their price objective on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Robert W. Baird started coverage on shares of Humana in a research report on Thursday, May 30th. They set a “neutral” rating and a $374.00 target price on the stock. Piper Sandler assumed coverage on shares of Humana in a research note on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price objective for the company. Finally, Morgan Stanley started coverage on shares of Humana in a research report on Monday, June 24th. They set an “equal weight” rating and a $374.00 target price on the stock. Thirteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $398.70.

Humana Trading Down 0.5 %

Shares of HUM stock opened at $310.41 on Friday. The company has a market capitalization of $37.40 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.56 and a beta of 0.50. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $357.71 and a 200 day moving average price of $345.63. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $530.54.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the previous year, the business posted $8.94 earnings per share. The company’s revenue was up 10.4% on a year-over-year basis. Research analysts forecast that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio is currently 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.